insights gathered from various sources including electronic health records (EHRs), insurance claims, patient registries, and other observational data. RWE, on the other hand, is the clinical evidence derived from RWD that is used to inform healthcare decisions.
The use of RWD and RWE is becoming critical for establishing efficacy and safety for SaMD. The FDA provides guidance on how to incorporate these elements into submissions to ensure that they meet regulatory standards. Understanding the definitions and applications of these concepts is the first step in preparing compliant submissions.

Key Regulatory References

To begin the preparation process, it is essential to familiarize yourself with FDA regulations such as:

• 21 CFR Part 11: Covers electronic records and electronic signatures, which are crucial for the digital submission of RWD.
• FDA Guidance on Real-World Evidence: Offers insights on the framework for using RWD and RWE in regulatory submissions.
• FDA Framework for Digital Health Technologies: Provides guidelines on how digital health technologies can be developed and assessed using RWE.

Understanding and applying these regulations and guidelines will lay a solid foundation for incorporating RWD and RWE into your submissions.

Step 1: Identify Relevant RWD Sources

The first step in creating a robust RWE section is identifying appropriate sources of RWD that align with your product and its intended use. Potential sources include:

• Electronic Health Records (EHRs): These are rich with patient data that can be utilized to derive real-world insights about the safety and effectiveness of your SaMD.
• Patient Registries: Disease-specific registries can provide insights into patient outcomes and treatment pathways.
• Insurance Claims Data: This data can reveal information about healthcare utilization and patient demographics.

In selecting these data sources, consider the following factors:

• The relevance and quality of the data to your product’s intended use.
• The population health context and whether it represents your target user base.
• Existing protocols or standards for data collection.

Utilizing a range of RWD sources enhances the credibility of the evidence and increases the likelihood of meeting FDA expectations for RWE submissions.

Step 2: Develop a Comprehensive RWE Strategy

After identifying your RWD sources, the next step is to develop a comprehensive RWE strategy. This should outline how the collected data will be analyzed and interpreted to support your product submission. Key elements for your RWE strategy include:

• Study Design: Whether to use observational studies, pragmatic studies, or virtual trials. This will depend on the nature of your product and data.
• Endpoints: Clearly define what endpoints you will measure, e.g., digital endpoints such as user engagement, health outcomes, or device utilization rates.
• Statistical Methods: Outline the statistical analysis plan that will be employed to analyze the data. Providing robust methodologies will strengthen your submission.

The RWE strategy should be aligned with FDA guidance which encourages a well-defined hypothesis and endpoint strategy for deriving evidence from RWD. This enhances the rigor of the analysis and supports claims about the effectiveness and safety of your product.

Step 3: Align RWE with Regulatory Requirements for SaMD Submissions

Ensuring alignment between your RWE and FDA regulatory requirements is critical. The submission format should be streamlined to fit the framework set forth by the FDA. Here are important considerations:

• Content Requirements: According to the FDA guidance, the RWE section must articulate the objectives, methods, and outcomes of the RWD analysis consistently throughout the submission process.
• Integration with Clinical Evidence: RWE should complement existing clinical evidence, explaining how it supports claims made in the submission.
• Quality and Validation of Data: Ensure that the RWD is representative of the intended population and that validation methods are described clearly.

By adhering closely to the FDA requirements for SaMD submissions, companies can create a narrative that effectively communicates the value of the RWE integrated into their product submissions.

Step 4: Create a Structured RWE Section Template

Having established the foundation for RWE in your submission, the next step is to develop an organized and easily digestible RWE section template. A comprehensive template might include:

Template Components

• Introduction: Briefly describe the purpose of the RWE inclusion within the context of your SaMD submission.
• Data Sources: Detail the RWD sources utilized, including their nature and relevance.
• Research Design: Outline the study design employed in analyzing the RWD, including the type of analysis (observational, pragmatic study, etc.).
• Endpoints: Clearly define the endpoints measured and how they align with clinical objectives.
• Statistical Analyses: Provide a concise summary of the statistical methods used to interpret the data and validate findings.
• Results: Present key findings derived from the RWE sources in a manner that is clear and supported by other evidence.
• Conclusion: Conclude with the implications of the RWE findings on product safety, effectiveness, and potential patient benefits.

This structured approach allows reviewers to navigate the RWE section easily, promoting clarity and understanding of how RWD informs your submission.

Step 5: Collaborate with Internal and External Experts

The integration of RWD and RWE into SaMD submissions often requires interdisciplinary collaboration. Engage with internal stakeholders such as clinical, regulatory, and quality teams. Additionally, consider collaborating with external experts in epidemiology and biostatistics to ensure that the analysis of your RWD adheres to industry standards.
By leveraging expertise across fields, you can enhance the quality and rigor of your RWE section, ultimately leading to more successful regulatory outcomes. Moreover, external experts can provide insights into current best practices and emerging trends in the use of RWE across the digital health landscape.

Step 6: Submission Process and Post-Submission Activities

Once your RWE section is integrated into the broader SaMD submission, ensure that it adheres to the established FDA submission guidelines. Be ready to address any questions from FDA reviewers regarding your RWE during the pre-market review process. Consider the following for an effective submission process:

• Completeness and Consistency: Verify that your submission is accurate and complete, with all appendices and supporting documents included.
• Post-Submission Queries: Be prepared to engage in discussions regarding your RWD and RWE, offering clarifications where necessary.
• Continuous Monitoring: After approval, monitor the real-world performance of your SaMD. This can provide further RWE to support future regulatory submissions or post-market requirements.

Collaboration with the FDA, as well as an understanding of the post-market landscape, will ensure that your SaMD remains compliant and able to adapt to regulatory changes.

Conclusion

The integration of RWD and RWE is increasingly important for the successful regulatory submission of SaMD and digital therapeutics. By following the systematic steps outlined in this article, digital health leaders can effectively incorporate these elements to meet FDA expectations. The emphasis on structure, clarity, and compliance throughout the RWE section will enhance the quality and potential success of submissions. As digital health continues to evolve, a well-prepared RWE strategy will facilitate regulatory engagement and ultimately benefit patient care.